The benefit and risk of addition of chemotherapy to EGFR tyrosine kinase inhibitors for EGFR-positive non-small cell lung cancer patients with brain metastases: a meta-analysis based on randomized controlled trials

• Published in: Frontiers in oncology Vol. 14; p. 1448336
• Main Authors: Chen, Zhigang, Fu, Xiang, Zhu, Lingping, Wen, Xiurong, Zhang, Shihao
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 21.10.2024
• Subjects: brain metastases; chemotherapy; EGFR; meta-analysis; non-small cell lung cancer; Oncology; tyrosine kinase inhibitors; non-small cell lung cancer; tyrosine kinase inhibitors; meta-analysis; chemotherapy; brain metastases; EGFR

Combining epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with chemotherapy (ETC) offers more advantages for patients with EGFR-positive non-small cell lung cancer (NSCLC) than using EGFR TKIs alone (ET). However, whether this conclusion applies to patients with brain metas...